Patiromer plus spironolactone in resistant hypertension and CKD

Area of Science:

• Nephrology
• Cardiology
• Clinical Pharmacology

Background:

• Resistant hypertension and chronic kidney disease (CKD) often require multiple antihypertensive medications.
• Spironolactone is effective for resistant hypertension but can cause hyperkalemia, especially in CKD patients.
• Managing potassium levels is crucial for optimizing treatment in these complex patients.

Purpose of the Study:

• To evaluate the efficacy of patiromer in enabling the use of spironolactone in patients with resistant hypertension and CKD.
• To assess the effect of patiromer on serum potassium levels and blood pressure control.

Main Methods:

• A phase 2, randomized, double-blind, placebo-controlled trial (AMBER) was conducted.
• Patients with resistant hypertension and CKD were randomized to receive either patiromer or placebo.
• The study assessed the ability to initiate or maintain spironolactone therapy and changes in serum potassium and blood pressure.

Main Results:

• Patiromer significantly reduced serum potassium levels compared to placebo.
• More patients in the patiromer group were able to initiate or maintain spironolactone therapy.
• Blood pressure reductions were observed in both groups, with no significant difference attributed to patiromer's potassium-lowering effect alone.

Conclusions:

• Patiromer is effective in lowering serum potassium and enabling the use of spironolactone in patients with resistant hypertension and CKD.
• This facilitates the use of a key medication for blood pressure control in a challenging patient population.
• Further studies are warranted to confirm long-term effects and optimal use.